DK2268669T3 - Bovin kolostrum omfattende antistoffer mod insulin til behandling af stofskifteforstyrrelsessygdomme - Google Patents
Bovin kolostrum omfattende antistoffer mod insulin til behandling af stofskifteforstyrrelsessygdommeInfo
- Publication number
- DK2268669T3 DK2268669T3 DK09720973.8T DK09720973T DK2268669T3 DK 2268669 T3 DK2268669 T3 DK 2268669T3 DK 09720973 T DK09720973 T DK 09720973T DK 2268669 T3 DK2268669 T3 DK 2268669T3
- Authority
- DK
- Denmark
- Prior art keywords
- insulin
- treatment
- metabolic disorders
- containing antibodies
- bovine colostrum
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 241000283690 Bos taurus Species 0.000 title 1
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 210000003022 colostrum Anatomy 0.000 title 1
- 235000021277 colostrum Nutrition 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3622708P | 2008-03-13 | 2008-03-13 | |
| PCT/IL2009/000273 WO2009113065A1 (en) | 2008-03-13 | 2009-03-11 | Immuno-modulating compositions for the treatment of immune-mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2268669T3 true DK2268669T3 (da) | 2017-11-20 |
Family
ID=40875006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09720973.8T DK2268669T3 (da) | 2008-03-13 | 2009-03-11 | Bovin kolostrum omfattende antistoffer mod insulin til behandling af stofskifteforstyrrelsessygdomme |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20110200610A1 (da) |
| EP (2) | EP2268669B1 (da) |
| AU (1) | AU2009222965B2 (da) |
| CA (1) | CA2718381A1 (da) |
| DK (1) | DK2268669T3 (da) |
| NZ (1) | NZ587901A (da) |
| WO (1) | WO2009113065A1 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2760096C (en) | 2009-04-27 | 2018-10-30 | Immuron Limited | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder. |
| EP2605791B1 (en) | 2010-08-17 | 2017-03-08 | Immuron Limited | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
| AP2013006940A0 (en) | 2010-11-23 | 2013-06-30 | Pantheryx Inc | Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications |
| IT1405998B1 (it) | 2010-12-09 | 2014-02-06 | Bionest Ltd | Gel polifunzionale contro la secchezza vaginale ad effetto diretto e ritardato |
| DE102011006809A1 (de) | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
| WO2013009843A1 (en) * | 2011-07-11 | 2013-01-17 | Camas Incorporated | Compositions against bacterial toxins |
| ITMI20112435A1 (it) * | 2011-12-30 | 2013-07-01 | Bionest Ltd | Profilassi e terapia delle malattie autoimmuni con citochine e fattori di crescita, antibatterici e anticorpi, isolati dai tessuti e dai liquidi biologici dei mammiferi |
| AU2013204801B2 (en) | 2012-05-23 | 2014-11-06 | Omniblend Innovation Pty Ltd | Composition and method for management of diabetes or pre-diabetes |
| US10464998B2 (en) * | 2013-10-30 | 2019-11-05 | Hadasit Medical Research Services And Development Limited | Anti-LPS enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis |
| EP3283515B1 (en) * | 2015-04-17 | 2020-03-11 | Ignova GmbH | Predictive biomarkers of clinical response to anti-lps immunoglobulin treatment |
| US20190134096A1 (en) * | 2016-05-06 | 2019-05-09 | Hadasit Medical Research Services & Development Limited | Hyperimmune colostrum in the modulation and treatment of conditions associated with the mammalian microbiome |
| CN111741762A (zh) * | 2017-11-24 | 2020-10-02 | 防御素治疗学公司 | 使用防御素预防和治疗移植物抗宿主病 |
| CN109010367A (zh) * | 2018-08-21 | 2018-12-18 | 姜伟 | 牛初乳粉及其制备方法、制剂和在制备治疗肿瘤药物中的应用 |
| US12070044B2 (en) | 2019-02-22 | 2024-08-27 | Aquero Canada Ltd. | Fortified milk compositions and their processes of preparation |
| WO2020176637A1 (en) | 2019-02-26 | 2020-09-03 | Pantheryx, Inc. | Compositions for management of disorders of the gastrointestinal tract |
| AU2020310953A1 (en) * | 2019-07-09 | 2022-02-17 | Aquero Canada Ltd. | Compositions, processes of production, sterilization, and health-promoting uses of lyophilized milk |
| WO2022103871A1 (en) * | 2020-11-10 | 2022-05-19 | Wyomingv Immune, Inc. | Therapeutic compositions for the treatment of covid-19 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1572220A (en) * | 1976-10-07 | 1980-07-30 | Mochida Pharm Co Ltd | Immunochemical process of measuring physiologically active substances |
| US5980896A (en) | 1989-06-30 | 1999-11-09 | Bristol-Myers Squibb Company | Antibodies reactive with human carcinomas |
| JP2879947B2 (ja) * | 1990-06-04 | 1999-04-05 | 鐘紡株式会社 | 毛髪改質剤 |
| US5369009A (en) * | 1992-04-17 | 1994-11-29 | Dana Farber Cancer Institute | Antibodies for P-glycoprotein encoded by the mdr1 gene and uses thereof |
| DE69432309D1 (de) | 1993-09-20 | 2003-04-24 | Anadis Ltd | Verfahren zur herstellung von immunoglobulinen aus colostrum und deren verwendung in pharmazeutischen zusammensetzungen |
| US6436401B1 (en) * | 1999-09-14 | 2002-08-20 | Milkhaus Laboratory, Inc. | Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies |
| WO2001087331A1 (fr) * | 2000-05-19 | 2001-11-22 | Sergey Georgievich Morozov | Produits pharmaceutiques destines a la suppression de troubles auto-immuns au moyen de fragments liant les idiotypes des anticorps anti-idiotypiques |
| WO2002078742A2 (en) * | 2001-01-30 | 2002-10-10 | The Lauridsen Group, Incorporated | Methods and compositions for treatment of immune dysfunction disorders |
| KR20100137015A (ko) | 2002-03-21 | 2010-12-29 | 아나디스 리미티드 | 불안정한 생활성 물질 및 포유동물 초유를 포함한 조성물, 제조 및 치료 방법 |
| CA2486801A1 (en) | 2002-05-21 | 2003-11-27 | Anadis Ltd | Method of prophylaxis of infection |
| AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
| AU2004291107B2 (en) | 2003-11-14 | 2010-09-30 | Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| US20090169566A1 (en) | 2004-11-22 | 2009-07-02 | Anadis Ltd. | Bioactive compositions |
| US8071101B2 (en) * | 2005-11-03 | 2011-12-06 | Avaxia Biologics, Inc. | Antibody therapy for treatment of diseases associated with gluten intolerance |
-
2009
- 2009-03-11 WO PCT/IL2009/000273 patent/WO2009113065A1/en not_active Ceased
- 2009-03-11 DK DK09720973.8T patent/DK2268669T3/da active
- 2009-03-11 AU AU2009222965A patent/AU2009222965B2/en not_active Ceased
- 2009-03-11 EP EP09720973.8A patent/EP2268669B1/en not_active Not-in-force
- 2009-03-11 CA CA2718381A patent/CA2718381A1/en not_active Abandoned
- 2009-03-11 EP EP17172590.6A patent/EP3231816A1/en not_active Withdrawn
- 2009-03-11 NZ NZ587901A patent/NZ587901A/xx unknown
-
2010
- 2010-09-10 US US12/879,129 patent/US20110200610A1/en not_active Abandoned
-
2012
- 2012-12-14 US US13/715,371 patent/US20130164302A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ587901A (en) | 2012-11-30 |
| EP2268669B1 (en) | 2017-10-18 |
| AU2009222965A1 (en) | 2009-09-17 |
| US20110200610A1 (en) | 2011-08-18 |
| EP2268669A1 (en) | 2011-01-05 |
| WO2009113065A1 (en) | 2009-09-17 |
| CA2718381A1 (en) | 2009-09-17 |
| US20130164302A1 (en) | 2013-06-27 |
| AU2009222965B2 (en) | 2014-10-02 |
| EP3231816A1 (en) | 2017-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2268669T3 (da) | Bovin kolostrum omfattende antistoffer mod insulin til behandling af stofskifteforstyrrelsessygdomme | |
| DK3321276T3 (da) | Fusionsproteiner til behandling af metaboliske lidelser | |
| LTC2152290I2 (lt) | Anti-il-5 antikūnų skyrimo būdai | |
| DK2114386T3 (da) | Farmaceutisk sammensætning til behandling af diabeteskomplikationer | |
| DK2269063T3 (da) | Forudsigelse af risiko for større uønskede hjertehændelser | |
| DK2643018T3 (da) | Anti-il-6-antistoffer til behandling af oral mucositis | |
| DK2262836T3 (da) | Antistof mod CSF-1R | |
| DK2776469T3 (da) | Antistofmolekyler med specificitet for human ox40 | |
| PL2621923T3 (pl) | Związki n-heteroarylu z mostkami cyklicznymi do leczenia chorób pasożytniczych | |
| DK2637690T3 (da) | Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration | |
| IL228030B (en) | Compounds for treating hyperuricemia and metabolic disorders associated with hyperuricemia | |
| DK2504005T3 (da) | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme | |
| IL229582B (en) | Anti-kir antibodies for the treatment of inflammatory disorders | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| DK3138854T3 (da) | Antistoffer mod CD40 | |
| DK3878859T5 (da) | Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse | |
| DK2177536T3 (da) | Antistoffer mod amyloid-beta-peptid | |
| DK2191831T3 (da) | Modificering af pirfenidon-behandling for patienter med atypisk leverfunktion | |
| PL2704734T3 (pl) | Kompozycja użyteczna do leczenia zaburzeń metabolizmu lipidów | |
| DK2451482T3 (da) | Kombinationsterapi til behandlingen af diabetes | |
| DK2585088T3 (da) | Sammensætning til forbedring af seksuel sundhed | |
| DK2734212T3 (da) | Sammensætninger omfattende diclofenac til behandling af postoperativ smerte | |
| PL2707015T5 (pl) | Liksysenatyd jako terapia uzupełniająca do insuliny bazalnej w cukrzycy typu 2 | |
| EE201300007A (et) | Kombineeritud ravimkoostis diabeedi ning ainevahetushirete raviks | |
| DK2552963T3 (da) | Humaniserede antistoffer mod CXCR4 til behandling af cancer |